Key terms

About DYN

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest DYN news

Mar 08 4:24am ET Dyne Therapeutics price target raised to $31 from $20 at Chardan Mar 07 11:25pm ET Buy Rating Affirmed for Dyne Therapeutics: Promising Clinical Data and Solid Financial Position Fuel Optimism Mar 06 11:45am ET Buy Rating Affirmed for Dyne Therapeutics Amidst Promising Drug Data and Strategic Market Positioning Mar 06 11:33am ET Dyne Therapeutics price target raised to $37 from $33 at Guggenheim Mar 06 7:36am ET Piper Sandler Keeps Their Buy Rating on Dyne Therapeutics (DYN) Mar 06 7:21am ET Dyne Therapeutics price target raised to $29 from $27 at Piper Sandler Mar 06 7:19am ET Dyne Therapeutics price target raised to $41 from $35 at Stifel Mar 06 6:37am ET Dyne Therapeutics: Strong Buy on Promising Clinical Data and Superior Therapeutic Platform Mar 05 8:25am ET Dyne Therapeutics files automatic mixed securities shelf Mar 05 7:42am ET Dyne Therapeutics price target raised to $47 from $44 at Oppenheimer Mar 05 7:42am ET Dyne Therapeutics reports Q4 EPS ($1.09), consensus (92c) Feb 20 6:07am ET Dyne Therapeutics initiated with a Buy at H.C. Wainwright Feb 09 8:29am ET Stifel Nicolaus Reaffirms Their Buy Rating on Dyne Therapeutics (DYN) Jan 31 1:00am ET Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Silence Therapeutics (SLN) and Dyne Therapeutics (DYN) Jan 26 2:58pm ET Dyne Therapeutics resumes trading, up 29% after report of takeover interest Jan 26 2:53pm ET Dyne Therapeutics trading resumes Jan 26 2:49pm ET Dyne Therapeutics seeing takeover interest, weighing options, Bloomberg says Jan 26 2:32pm ET Dyne Therapeutics jumps as Bloomberg says company seeing takeover interest Jan 26 2:29pm ET Dyne Therapeutics seeing takeover interest, weighing options, Bloomberg says Jan 26 2:28pm ET Dyne Therapeutics trading halted, volatility trading pause Jan 08 7:41am ET Dyne Therapeutics price target lowered to $27 from $29 at Piper Sandler Jan 08 7:37am ET Piper Sandler Keeps Their Buy Rating on Dyne Therapeutics (DYN) Jan 04 10:53pm ET Dyne Therapeutics 17.15M share Spot Secondary priced at $17.50 Jan 03 11:55pm ET Optimistic Outlook on Dyne Therapeutics Backed by Promising Early Trial Results Jan 03 4:27pm ET Dyne Therapeutics announces $175M common stock offering Jan 03 12:23pm ET Dyne data validate Avidity Biosciences study, says Wells Fargo Jan 03 10:42am ET Dyne Therapeutics price target raised to $56 from $27 at Raymond James Jan 03 6:35am ET Dyne Therapeutics reports ‘positive’ initial data from ACHIEVE trial of DYNE-101 Dec 14 1:31pm ET Oppenheimer, Wedbush say buy these biotech stocks for 2024 Dec 14 1:31pm ET Oppenheimer, Wedbush say buy these biotech stocks for 2024

No recent news articles are available for DYN

No recent press releases are available for DYN

DYN Financials

1-year income & revenue

Key terms

DYN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

DYN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms